Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Pfizer shuffles its deck post-Seagen
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
